Combined oral contraceptives and antiretroviral PK/PD in Malawian women: Pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 2, 2011, Pages

  Stuart, Gretchen S ^a   Moses, Agnes ^b   Corbett, Amanda ^c   Phiri, Grace ^b   Kumwenda, Wiza ^b   Mkandawire, Nkhafwire ^b   Chintedze, Joseph ^b   Malunga, Gabriel ^b   Hosseinipour, Mina ^a   Cohen, Myron S ^a   Stanczyk, Frank Z ^d   Kashuba, Angela D M ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA PROJECT   (Malawi)

^c School of Pharmacy   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2B6; ETHINYLESTRADIOL PLUS NORGESTREL; GENERIC DRUG; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE;

ANOVULATION; AREA UNDER THE CURVE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG FORMULATION; FEASIBILITY STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LETTER; MALAWI; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADULT; ANTI-HIV AGENTS; AREA UNDER CURVE; CONTRACEPTIVES, ORAL, COMBINED; DRUG THERAPY, COMBINATION; ETHINYL ESTRADIOL; FEASIBILITY STUDIES; FEMALE; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; LAMIVUDINE; LEVONORGESTREL; MALAWI; NEVIRAPINE; NORGESTREL; OVULATION INHIBITION; PROGESTERONE; STAVUDINE; YOUNG ADULT;

EID: 80052995163     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31822b8bf8     Document Type: Letter

References (27)

1. UNAIDS report on the global HIV/AIDS epidemic: 2010. Available at: http://www.unaids. org/globalreport/documents/20101123-Global Report-full-en.pdf. Accessed April 15, 2011.
2. UNAIDS. AIDS scorecards. Overview UNAIDS report on the global AIDS epidemic:2010. Available at: http://www.unaids.org/globalreport/AIDSScorecards. htm. Accessed April 15, 2011.
3. Reynolds HW, Janowitz B, Wilcher R, et al. Contraception to prevent HIV-positive births: current contribution and potential cost savings in PEPFAR countries. Sex Transm Infect. 2008,84:ii49-ii53.
4. United Nations. World contraceptive use 2009. Available at: www.un.org/esa/population/publications/contraceptive2009/contraceptive 2009.htm. Accessed April 15, 2011.
5. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services; January 10, 2011. Available at: www.aidsinfo.nih.gov/ContentFiles/Adult andAdolescentGL.pdf. Accessed April 15, 2011.
6. Kaletra. Physician prescribing information. North Chicago, IL: Abbott Laboratories.
7. Viramune. Physician prescribing information. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc; 2005.
8. Leitz G MD, McDonough M, et al. Nevirapine (Viramune) and ethinyl estradiol/noethindrone [Ortho-Novum 1/35 (21 pack) EE/NET] interaction study in HIV-1 infected-women. Abstract #89. Paper presented at: 7th Conference on Retroviruses and Opportunistic Infections; January 31 to February 4 2000; San Francisco, CA.
9. Sevinsky H, Eley T, Persson A, et al. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther. 2011;16(2):149-156.
10. Carten M KJ, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel and efavirenz. Abstract 934. Presented at: 17th Conference on Retroviruses and Opportunistic Infections; 2010; San Francisco, CA.
11. Database of Antiretroviral Drug Interactions. http://hivinsite.ucsf.edu/ insite?page=ar-00-02& post=7. Accessed April 15, 2011.
12. World Health Organization. Review of priorities in research. Hormonal contraception and IUDs and HIV infection. Report of a technical meeting. Geneva; 13-15 March, 2007. http://whqlibdoc. who.int/hq/2010/WHO-RHR-10.21-eng.pdf. Accessed April 15, 2011.
13. Goldzieher JW, Stanczyk FZ. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception. 2008;78:4-9.
14. FEM-PrEP Project. FHI to initiate orderly closure of FEM-PrEP. Available at: http://www.fhi.org/en/Research/Projects/FEM-PrEP.htm. Accessed April 18, 2011
15. Treating HIV-infected people with antiretrovirals protects partners from infection. Findings result from NIH-funded international study. NIH News Release. Available at: www.niaid. nih.gov/news/newsreleases/2011/Pages/HPTN052. aspx. Accessed April 15, 2011.
16. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/norethindrone when administered concurrently to HIV-infected women. J Acquir Immune Defic Syndr. 2002; 29:471-477. (Pubitemid 34456338)
17. Hosseinipour MC, Corbett AH, Kanyama C, et al. Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults. AIDS. 2007;21:59-64. (Pubitemid 44912537)
18. Rezk NL, Tidwell RR, Kashuba AD. Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatog B Analyt Techno Biomed Life Sci. 2003;791: 137-147. (Pubitemid 36638747)
19. Stanczyk FZ, Hiroi M, Goebelsmann U, et al. Radioimmunoassay of serum d-norgestrel in women following oral and intravaginal administration. Contraception. 1975;12:279-298.
20. Price TM, Dupuis RE, Carr BR, et al. Singleand multiple-dose pharmacokinetics of a low-dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol. 1993;168: 1400-1406. (Pubitemid 23153279)
21. Speroff L, Fritz MA. Female infertility. In: Leon Speroff and Marc A. Fritz, eds. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1013-1068.
22. Grimes DA, Godwin AJ, Rubin A, et al. Ovulation and follicular development associated with three low-dose oral contraceptives: a randomized controlled trial. Obstet Gynecol. 1994;83:29-34. (Pubitemid 24027376)
23. El-Ibiary SY, Cocohoba JM. Effects of HIV antiretrovirals on the pharmacokinetics of hormonal contraceptives. Eur J Contracept Reprod Health Care. 2008;13:123-132. (Pubitemid 352000659)
24. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006;43: 783-786. (Pubitemid 44330746)
25. Speroff L, Fritz MA. Oral contraception. In: Leon Speroff and Marc A. Fritz, eds. Clinical Gynecologic Endocrinology and Infertility. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:861-942.
26. Trussell J. Contraceptive failure in the United States. Contraception. 2011;83(5):397-404. [Epub ahead of print].
27. Sullivan TM, Bertrand JT, Rice J, et al. Skewed contraceptive method mix: why it happens, why it matters. J Biosoc Sci. 2006; 38:501-521. (Pubitemid 44418357)